During the past decade, Ziekenhuis Oost-Limburg - Campus Sint-Jan conducted 24 clinical trials. In the 10-year time frame, 24 clinical trials started and 16 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 10 clinical trials were completed. i.e. 83.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Ziekenhuis Oost-Limburg - Campus Sint-Jan" #1 sponsor was "Boehringer Ingelheim" with 4 trials, followed by "Elixir Medical Corporation" with 3 trials sponsored, "Eidos Therapeutics, a BridgeBio company" with 2 trials sponsored, "Flanders Medical Research Program" with 2 trials sponsored and "Hoffmann-La Roche" with 2 trials sponsored. Other sponsors include 25 different institutions and companies that sponsored additional 31 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Ziekenhuis Oost-Limburg - Campus Sint-Jan" #1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "AF Schimetta GMbH" with 1 trials as a collaborator, "Bard Ltd" with 1 trials as a collaborator, "Boston Scientific Corporation" with 1 trials as a collaborator and "Chiltern International Inc." with 1 trials as a collaborator. Other collaborators include 3 different institutions and companies that were collaborators in the rest 13 trials.

According to Clinical.Site data, the most researched conditions in "Ziekenhuis Oost-Limburg - Campus Sint-Jan" are "Coronary Artery Disease" (7 trials), "Critical Limb Ischemia" (4 trials), "Heart Failure" (3 trials), "Atrial Fibrillation" (2 trials) and "Cardiovascular Disease" (2 trials). Many other conditions were trialed in "Ziekenhuis Oost-Limburg - Campus Sint-Jan" in a lesser frequency.

Most popular intervention types in "Ziekenhuis Oost-Limburg - Campus Sint-Jan" are "Device" (23 trials), "Drug" (15 trials), "Biological" (2 trials), "Other" (2 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Empagliflozin" (3 trials), "bococizumab (PF-04950615)" (2 trials), "Acoramidis (AG10)" (1 trials) and "Angio" (1 trials). Other intervention names were less common.

The vast majority of trials in "Ziekenhuis Oost-Limburg - Campus Sint-Jan" are 41 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Ziekenhuis Oost-Limburg - Campus Sint-Jan". undefined are not yet recruiting, 8 are recruiting, 3 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 23 completed trials in Ziekenhuis Oost-Limburg - Campus Sint-Jan, 1 suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Ziekenhuis Oost-Limburg - Campus Sint-Jan, 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 16 trials that are defined as “Not Applicable".